Geographic atrophy (GA) is a condition that typically progresses slowly, with lesions expanding by about 1 square millimeter per year, leading to blind spots due to retinal deterioration. Treatment ...

Please provide your email address to receive an email when new articles are posted on . WAILEA, Hawaii — When making treatment decisions for geographic atrophy, atrophy geometry, lesion size and ...

Please provide your email address to receive an email when new articles are posted on . I do think that complement therapy can be considered for many patients with geographic atrophy, but the risks ...

Ocugen, Inc. has completed enrollment in the Phase 2 portion of its clinical trial for OCU410, a novel gene therapy aimed at treating geographic atrophy (GA) associated with dry age-related macular ...

The FDA approved the usage of Izervay (avacincaptad pegol) for the treatment of geographic atrophy secondary to age-related macular degeneration. Geographic atrophy (GA) secondary to age-related ...

CTx001 has previously received FDA IND clearance and will be evaluated in Opti-GAIN, a first-in-human Phase I/II clinical trial MUNICH, Jan. 8, 2026 /PRNewswire/ -- Complement Therapeutics GmbH (CTx), ...

Apellis Pharmaceuticals, Inc. announced that the Therapeutic Goods Administration (TGA) in Australia has approved its treatment SYFOVRE® (pegcetacoplan) for adult patients suffering from geographic ...